Study on the clinical efficacy and safety of methylprednisolone and cyclophosphamide combined with ⁹⁹Tc-MDP in the treatment of thyroid-associated ophthalmopathy

ObjectiveTo investigate the clinical efficacy and safety of methylprednisolone and cyclophosphamide combined with ⁹⁹Tc-MDP in the treatment of thyroid-associated ophthalmopathy(TAO).

MethodsFifty patients with TAO were divided into the control group(22 cases) and observation group(28 cases) according to the treatment schemes.The control group was treated with methylprednisolone and cyclophosphamide, and the observation group was treated with methylprednisolone and cyclophosphamide combined with ⁹⁹Tc-MDP.The thickness of extraocular muscle, clinical activity score(CAS) and severity of disease before and after treatment, and incidence rate of adverse reactions were compared between two groups.

ResultsBefore treatment, the differences of the CAS score, thickness of extraocular muscle and severity of disease between two groups were not statistically significant(P>0.05).After treatment, the CAS score and severity of disease in two groups significantly decreased compared with before treatment(P < 0.01), the thickness of extraocular muscle in the observation group was significantly lower than that before treatment, and the CAS score, severity of disease and thickness of extraocular muscle in observation group were lower than those in control group(P < 0.05 to P < 0.01).The incidence rate of adverse reactions during treatment in observation group(5.36%) was lower than that in control group(20.45%)(P < 0.05).

ConclusionsThe methylprednisolone and cyclophosphamide combined with ⁹⁹Tc-MDP in the treatment of TAO can effectively improve the clinical efficacy and reduce the occurrence of adverse reactions, which is worthy of clinical promotion.